Histone Deacetylase Inhibitors — Epidrugs for Neurological Disorders

Dr. Shabir Ahmad Ganai is currently working as Assistant Professor Cum Junior Scientist, Division of Basic Sciences and Humanities, Faculty of Agriculture, SKUAST-Kashmir, Wadura, Sopore, 193201, Jammu & Kashmir, India. He has done his masters in Biochemistry from Bangalore University (2005-2007) and earned his Ph.D. from elite SASTRA University (2009-2014). Later, he did his post-doctorate from National Brain Research Centre, Haryana, India. He has also served as research fellow in SKUAST-Kashmir. His research interests are focused on understanding the modulations of the nuclear geometry and post-translational modifications during treatment with structurally distinct HDAC inhibitors. He has been actively involved in designing the target-selective inhibitors against Class II HDACs using various bioinformatics tools. Dr. Shabir Ahmad Ganai has published more than 20 research articles and one editorial in high impact factor international Journals. He has also served as guest editor for a thematic issue (Epigenetics: A novel frontier for drug discovery) published by Current Medicinal Chemistry. In addition, he serves as a referee for many reputed international journals like Current Drug Targets, PLOS ONE and Medicinal Chemistry Research.  He is an active member of many national and international societies including, The International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT).

Chapter 1. Role of Epigenetics in neurological diseases.- Chapter 2. Epigenetic enzymes and the drawbacks of conventional therapeutic regimens.- Chapter 3. Distinct classes of HDACs.- Chapter 4. HDAC implications in neurological diseases.- Chapter 5. HDAC inhibitors and their structurally distinct groups.- Chapter 6. HDAC inhibitors as novel therapeutic option against therapeutically challenging neurological disorders.- Chapter 7. Current Challenges with HDAC inhibitor based therapeutic intervention against neurological maladies.- Chapter 8. Escalating need of isoform selective inhibitors for enhanced therapeutic efficacy.- Chapter 9. Combinatorial therapeutic regimens using HDAC inhibitors in conjunction with conventional therapeutic agents.- Chapter 10. Future directions of epigenetic research in tackling neurological complications.